Mount Sinai Opens Psychedelics Research Center

A new facility for psychedelics research, the Center for Psychedelic Psychotherapy and Trauma Research, was recently opened in New York City. The center follows a multifaceted research and clinical approach to finding new and more effective treatments for anxiety, depression, PTSD and other conditions linked to stress in both the civilian and veteran populations. The facility’s research will center on the study of psilocybin, MDMA and other psychedelic substances.

MDMA, which is commonly known as ecstasy, is a psychoactive drug that may be used as a PTSD therapy treatment. Earlier in 2017, the U.S. FDA granted Breakthrough Therapy Designation status to MDMA-assisted psychotherapy. Currently, phase 3 trials on this psychoactive compound are in progress, despite the fact that MDMA has not yet been approved for clinical use.

MDMA-assisted therapy is a new method of treatment, and while preliminary clinical study results show promise, more information on the drug is required to ascertain how the therapy will work in individuals who have complicated mental health issues.

In addition to this research, the center will also conduct clinical trials needed for MDMA and other psychedelic-assisted therapy treatments to be adopted. The facility will also carry out extensive research on how these treatments affect a patient’s body. The information gathered will be used to help researchers scale and deliver these treatments in the way most effective to patients.

Rachel Yehuda, a professor of neuroscience and psychiatry, has been appointed the center’s head. Yehuda recently finished an MDMA-assisted psychotherapy clinician training been sponsored by MAPS (Multidisciplinary Association for Psychedelic Studies).

Yehuda stated that individuals who have undergone MDMA-assisted psychotherapy reported increased interpersonal trust, connectedness, and compassion towards others and self as well as feelings of introspection. She then explained that it was critical to listen to an individual’s subjective experiences with these psychoactive compounds then learn more about the therapeutic possibilities they possess through extensive clinical trials.

The center’s activities lie in four vital areas:

  • Public education and collaboration.
    • This will help promote scientific collaborations and also develop a layout for the public that discusses the use of psychedelic-assisted psychotherapy in depth.
  • Translational neuroscience and basic science research.
    • The facility will look into the mechanisms of psychedelics through the use of translational and clinical approaches, with the aim of studying the effects of these treatments on cellular biology and brain function.
  • Clinical trials.
    • The facility will conduct trials and assess the delivery of psychedelic-assisted therapy for individuals with post-traumatic stress disorder.
  • Education and training
    • Clinicians who are trained, licensed and cleared in psychedelic-assisted psychotherapy training will set up a program to teach others in the mental health community.

Dennis S. Carney, dean of Icahn School of Medicine at Mount Sinai, which established the facility, stated that under the leadership of Yehuda, the newly established facility would offer a better understanding of how psychedelic-assisted psychotherapy treatments work.

Things are also heating up in Canada within the psychedelics space. Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) has signed NDAs aimed at establishing research collaborations for the rapid development of products starting in Q4 2020.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://ibn.fm/PULL

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050